TABLE 4.
Previous studies reported similar genotypes of our studies from patients with triplicated α‐globin genes and heterozygous β‐thalassemia
| Transfusion‐dependent | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Population | β‐genotype | Number of patients | Hb (g/dl) Mean ± SD | Hb Less than 9 (g/dl) | No. of patients | Regular | Irregular | Splenectomy | References |
| Iranian | IVSII‐I(G‐A)/ wt | 18 | 9.65 ± 0.2 | ? | 14 | 6 | 8 | 2 | [14] |
| Iranian | IVSII‐I(G‐A)/ wt | 5 | 8.56 ± 0.7 | 3 | 4 | 2 | 2 | 2 | [19] |
| Italian | IVSII‐I(G‐A)/ wt | 3 | 11 ± 1.12 | 0 | 0 | 0 | 0 | 0 | [29] |
| Brazilian | IVSII‐I(G‐A)/ wt | 2 | 10.2 ± 1.6 | 0 | 0 | 0 | 0 | 0 | [11] |
| Our study | IVSII‐I(G‐A)/ wt | 9 | 10.65 ± 1.4 | 1 | 0 | 0 | 0 | 0 | |
| Total | IVSII‐I(G‐A)/ wt | 37 | 9.94 ± 1.43 | 4 | 18 | 8 | 10 | 4 | |
| Total excluding [14, 19] | IVSII‐I(G‐A)/ wt | 14 | 10.76 ± 1.26 | 1 | 0 | 0 | 0 | 0 | |
| Iranian | CD15(TGG‐TGA)/ wt | 1 | 8.2 | 1 | 1 | 1 | 0 | 1 | [14] |
| Our study | CD15(TGG‐TGA)/ wt | 2 | 10.9 ± 1.55 | 0 | 0 | 0 | 0 | 0 | |
| Total | CD15(TGG‐TGA)/ wt | 3 | 9.55 ± 1.9 | 1 | 1 | 1 | 0 | 1 | |
| Greece | CD39 (C > T)/ wt | 4 | 10.4 ± 1.1 | 0 | 0 | 0 | 0 | 0 | [15] |
| European ancestry | CD39 (C > T)/ wt | 5 | 9.1 ± 0.84 | 2 | 2 | 1 | 1 | 0 | [30] |
| ? | CD39 (C > T)/ wt | 9 | 9.2 ± 1.6 | 4 | 4 | 0 | 4 | 2 | [3] |
| Italian | CD39 (C > T)/ wt | 18 | 9.93 ± 1.01 | 4 | 3 | 0 | 3 | 3 | [29] |
| Italian | CD39 (C > T)/ wt | 1 | 8.6 | 1 | 0 | 0 | 0 | 0 | [31] |
| Dutch | CD39 (C > T)/ wt | 15 | 10.1 | ? | 0 | 0 | 0 | 0 | [10] |
| Greece | CD39 (C > T)/ wt | 6 | 9.86 ± 1.67 | 2 | 2 | 0 | 2 | ? | [36] |
| Our study | CD39 (C > T)/ wt | 1 | 11.5 | 0 | 0 | 0 | 0 | 0 | |
| Total | CD39 (C > T)/ wt | 59 | 9.31 ± 1.22 | 13 | 11 | 1 | 10 | 5 | |
| ? | IVSI‐110(G > A)/ wt | 3 | 10.1 ± 2.3 | 1 | 0 | 0 | 0 | 0 | [3] |
| Italian | IVSI‐110(G > A)/ wt | 1 | 8.9 | 1 | 0 | 0 | 0 | 1 | [29] |
| Gypsy | IVSI‐110(G > A)/ wt | 1 | 8.5 | 1 | 0 | 0 | 0 | 0 | [32] |
| Dutch | IVSI‐110(G > A)/ wt | 10 | 11.2 | ? | 0 | 0 | 0 | 0 | [10] |
| Greece | IVSI‐110(G > A)/ wt | 2 | 8.7 ± 0.28 | 2 | 0 | 0 | 0 | 0 | [36] |
| Our study | IVSI‐110(G > A)/ wt | 1 | 10.2 | 0 | 0 | 0 | 0 | 0 | |
| Total | IVSI‐110(G > A)/ wt | 18 | 9.6 ± 1.0 | 5 | 0 | 0 | 0 | 0 | |
| Iranian | IVSI‐5(G > C)/ wt | 3 | 7.9 | 3 | 2 | 1 | 1 | 1 | [14] |
| Iranian | IVSI‐5(G > C)/ wt | 2 | 8 ± 0.42 | 2 | 2 | 1 | 1 | 1 | [19] |
| Iranian | IVSI‐5(G > C)/ wt | 2 | 12.1 ± 1.7 | 0 | 0 | 0 | 0 | 0 | [28] |
| ? | IVSI‐5(G > C)/ wt | 2 | 10.8 ± 0.5 | 0 | 0 | 0 | 0 | 0 | [3] |
| Our study | IVSI‐5(G > C)/ wt | 1 | 9.0 | 0 | 0 | 0 | 0 | 0 | |
| Total | IVSI‐5(G > C)/ wt | 10 | 9.56 ± 1.83 | 5 | 4 | 2 | 2 | 2 | |
| Total excluding [14, 19] | IVSI‐5(G > C)/ wt | 5 | 10.63 ± 1.55 | 0 | 0 | 0 | 0 | 0 | |
| ? | IVSI‐I(G > A)/ wt | 2 | 9 ± 1.4 | 1 | 0 | 0 | 0 | 1 | [3] |
| Greece | IVSI‐I(G > A)/ wt | 8 | 9.2 ± 1.3 | 3 | 0 | 0 | 0 | 0 | [15] |
| Greece | IVSI‐I(G > A)/ wt | 7 | 9.1 ± 1.8 | 4 | 4 | 0 | 4 | ? | [36] |
| Iranian | IVSI‐I(G > A)/ wt | 2 | 10.1 | ? | 2 | 1 | 1 | 1 | [14] |
| Italian | IVSI‐I(G > A)/ wt | 6 | 10.58 ± 1.2 | ? | 0 | 0 | 0 | 1 | [29] |
| Our study | IVSI‐I(G > A)/ wt | 1 | 10.6 | 0 | 0 | 0 | 0 | 0 | |
| Total | IVSI‐I(G > A)/ wt | 26 | 9.76 ± 1.0 | 8 | 6 | 1 | 5 | 3 | |
| Total excluding [14] | IVSI‐I(G > A)/ wt | 24 | 9.70 ± 0.9 | 8 | 4 | 0 | 4 | 2 | |
| Iranian | CD44(‐C)/ wt | 1 | 9.6 | 0 | 0 | 0 | 0 | 0 | [14] |
| Iranian | CD44(‐C)/ wt | 1 | 9.8 | 0 | 0 | 0 | 0 | 0 | [19] |
| Our study | CD44(‐C)/ wt | 5 | 10.4 ± 0.1 | 0 | 0 | 0 | 0 | 0 | |
| Iranian | CD8(‐AA)/ wt | 2 | 9.4 ± 3.7 | 1 | 1 | 1 | 0 | 1 | [14] |
| Iranian | CD8(‐AA)/ wt | 1 | 7.8 | 1 | 1 | 1 | 0 | 0 | [19] |
| Our study | CD8(‐AA)/ wt | 3 | 10.2 ± 1.1 | 0 | 0 | 0 | 0 | 0 | |
| Iranian | CD36/37‐T/wt | 3 | 8.5 ± 1.83 | 2 | 2 | 1 | 1 | 0 | [14] |
| Iranian | CD36/37‐T/wt | 1 | 10.1 | 0 | 0 | 0 | 0 | 0 | [19] |
| Our study | CD36/37‐T/wt | 15 | 10.5 ± 1.6 | 1 | 0 | 0 | 0 | 0 | |
| Iranian | Indian deletion/wt | 1 | 7.3 | 1 | 1 | 1 | 0 | 0 | [14] |
| Our study | Indian deletion/ wt | 3 | 12. ± 0.2 | 0 | 0 | 0 | 0 | 0 | |
| Dutch | CD5(‐CT)/ wt | 11 | 8.7 | ? | 0 | 0 | 0 | 0 | [10] |
| Our study | CD5(‐CT)/ wt | 1 | 10.2 | 0 | 0 | 0 | 0 | 0 | |
| Dutch | IVSI‐6(T‐C)/ wt | 15 | 14 | 0 | 0 | 0 | 0 | 0 | [10] |
| Our study | IVSI‐6(T‐C)/ wt | 2 | 12. ± 0.3 | 0 | 0 | 0 | 0 | 0 | |
| Total | 218 | 9.9 ± 1.2 | 42 | 45 | 17 | 28 | 17 | ||
| Total excluding [14, 19] | 177 | 10.3 ± 1.0 | 28 | 15 | 1 | 14 | 7 | ||